8ª Edição

EORTC Study 1325-MG/Keynote-054 affirms pembrolizumab as an adjuvant therapy option for melanoma

per: Grupo Oncoclínicas
EORTC Study 1325-MG/Keynote-054 affirms pembrolizumab as an adjuvant therapy option for melanoma

Scientific commission

Carolina Cardoso
Carolina Cardoso
Frederico A. Nunes
Frederico A. Nunes
Rodrigo Perez Pereira
Rodrigo Perez Pereira
Sérgio Jobim de Azevedo
Sérgio Jobim de Azevedo

Contributors

Caroline Albuquerque
Caroline Albuquerque
Marco Lessa
Marco Lessa

A new analysis looked at health-related quality of life data of melanoma patients treated with pembrolizumab. This measure refers to the individual’s perception of their own physical and mental health over time. The conclusion of the EORTC 1325-MG/Keynote-054 study was that pembrolizumab does not result in a significant decline in health-related quality of life in melanoma patients compared to placebo, supporting the drug’s indication in this setting.

According to Marco Lessa, oncologist at the Núcleo de Oncologia da Bahia (NOB), a clinic of the Grupo Oncoclínicas in Salvador, “the medicine should not be worse than the disease. The oncologic treatment should not impose more suffering than the cancer itself, even if it increases the patient’s life span,” he says.

The objective of adjuvant therapy is to reduce the risk of the disease returning, says Caroline Albuquerque, oncologist at Oncoclínicas Porto Alegre, part of the Grupo Oncoclínicas in Rio Grande do Sul. “However, we need to consider the quality of life of patients, since they have a chance of already being cured with surgery alone.”

Read the full article with all the details of this study.

Access the full article of this study
Download
Share
Or share the link
Link copied to your desktop.L